SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports ...

Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...

IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company ...

The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of ...

Ventus Therapeutics enters agreement with Genentech to discover and develop small-molecule medicines using Ventus’ ReSOLVE platform: Waltham, Massachusetts Thursday, October 23, ...

Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its ...

The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while refocusing and finding a new R&D leader.

Cardiff Oncology's onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar ...